Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) is a clinical-stage leader developing TCR-T cell therapies targeting neoantigens in solid tumors. This page provides centralized access to all material updates from this innovator in precision immuno-oncology.
Investors and researchers will find essential announcements including clinical trial progress, regulatory milestones, and scientific collaborations. Our curated feed ensures timely access to verified updates on therapeutic developments and corporate strategy.
Key content areas include updates on TCR-T platform advancements, partnership announcements with research institutions, and financial disclosures. All information is sourced directly from company filings and authorized communications.
Bookmark this page for efficient tracking of Alaunos' pioneering work in targeting RAS-mutant cancers and other genomic drivers. Check regularly for developments in their mission to transform solid tumor treatment through engineered cellular therapies.
Alaunos Therapeutics has announced a poster presentation at the 25th Annual Meeting of the American Society of Gene and Cell Therapy, showcasing new preclinical data on its mbIL-15 program. This innovative cell therapy targets hotspot mutations in solid tumors, demonstrating enhanced survival capabilities. The research highlights the effectiveness of Sleeping Beauty transposed mbIL-15 TCR-T cells in improving clinical responses. The company plans to file an IND application for this program in H2 2023. The poster presentation is scheduled for May 16, 2022.
Alaunos Therapeutics has successfully dosed the first patient in its Phase 1/2 TCR-T Library trial targeting KRAS, TP53, and EGFR mutations in solid tumors. This milestone represents the first use of the company’s non-viral TCR-T cell therapy, manufactured in-house at its cGMP facility. The open-label study, conducted at MD Anderson Cancer Center, aims to determine the maximum tolerated dose and safety profile across various solid tumor types. Initial data is expected to be reported in the second half of 2022.
Alaunos Therapeutics, Inc. (TCRT) announced its fourth quarter and full year financial results for 2021, reporting a net loss of $11.8 million for Q4 and $78.8 million for the full year. Research and development expenses decreased to $8.2 million in Q4 from $14.0 million year-over-year. Significant milestones include the first patient consented in the Phase 1/2 TCR-T Library trial targeting solid tumors and an extended CRADA with the National Cancer Institute. As of December 31, 2021, the company had cash reserves of approximately $76.1 million.
Alaunos Therapeutics, Inc. (TCRT) will announce its fourth-quarter financial results for 2021 on March 30, 2022, before U.S. market open. Following this, a conference call and webcast will be held at 8:30 a.m. ET for a corporate update and financial review. Investors can access the call by dialing in or through a live webcast on the company’s website. Alaunos specializes in oncology-focused cell therapies, leveraging its Sleeping Beauty gene transfer platform, and has collaborations with notable institutions like MD Anderson Cancer Center and the National Cancer Institute.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced that CEO Kevin S. Boyle Sr. and VP of Research & Development Drew Deniger will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 9:20am ET. The presentation will be available via a live webcast on the company’s website, with an archived replay accessible for 30 days. Alaunos focuses on oncology cell therapies, developing T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer technology and targeting major tumor-related mutations.
